Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer's disease: randomized, placebo-controlled, double-Blind, phase I clinical trial
Journal of Alzheimer's Disease Published January 1, 2022
More on these topics
Browse all publications →-
2026 · Nat Med
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease
-
2025 · Neurotherapeutics
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease
-
2025 · J Prev Alzheimers Dis
Donanemab: Appropriate use recommendations
-
2024 · Alzheimer's Association International Conference (AAIC)
Navigating the Complexities of Alzheimer's Clinical Trials: The Perils of Small Molecule Studies and the Risk of Fraudulent Practices